Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth’s Pristiq (corr.)

Executive Summary

Wyeth's antidepressant Pristiq (desvenlafaxine) is a racemic mixture and the succinate salt of a metabolite of venlafaxine (Wyeth's Effexor), not a single enantiomer as stated in the "The Pink Sheet" Jan. 15 (1"The Pink Sheet" Jan. 15, 2007, p. 26). FDA is considering the Effexor XR follow-on to be a new molecular entity, Wyeth says...

You may also be interested in...

2007 NME Prospects Plentiful For Wyeth, Novartis – Other Firms Fall Short

The year 2007 holds the potential to fatten Wyeth's new drug lineup: after a lean 2006, when no Wyeth new molecular entities were approved, the company leads the industry in potential NME approvals for the coming year

Reimbursement Questions Jeopardize Hillrom/Bardy Merger

Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.

Boston Scientific Pays More Than $1Bn For Lumenis’ Surgical Laser Business

Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts